Sirius Medical Debuts at Major U.S. Breast Surgeons Conference

Introducing Pintuition® powered by GPSDetectTM for surgical navigation that simply makes sense

Sirius Medical has announced their participation at the American Society of Breast Surgeons 23rd Annual Meeting, April 6-10 at the Wynn Las Vegas Resort. Sirius Medical, a leader in tumor navigation technology, will debut Pintuition powered by GPSDetect, a unique navigation system to locate and excise non-palpable breast lesions.

Sirius Medical Debuts At Major U.s. Breast Surgeons Conference

Pintuition is CE marked and FDA 510(k) cleared and over 2,500 procedures have been performed worldwide. The system is an intuitive, wire-free, surgical navigation system with multisensory GPSDetect that provides real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors easily and accurately.

“Pintuition is true navigation technology,” said Barry Rosen, MD, FACS, oncologist, Chicago, IL. “While localization gives direction, this system provides me with distance, direction, and precise location. It is simple and intuitive.”

In addition to technology innovation, Sirius Medical has a strong passion for value-based healthcare. Aiming to improve sustainable access to innovative surgical cancer care worldwide, Sirius Medical has developed unique financial models and SiriusLinkTM, to help physicians and hospitals manage growth and control costs. SiriusLink is an innovative data science application that enables hospital teams to achieve process improvement.

Bart Vrouenraets, MD, PhD, surgeon and head of the department of quality at the OLVG Hospital, Netherlands, will present a poster, SiriusLink – Surgical Oncology Process Improvement, at the conference on April 7th.

“We are excited to be a part of this premier breast surgeon conference,” says Bram Schermers, CEO Sirius Medical. “In the short time we have been in the U.S. market, physicians and administrators are embracing our technology and its simplicity, precision and affordability.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”